Clinical Trials Logo
  1. Home
  2. Microscopic Polyangiitis
  3. NCT01613599

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Microscopic Polyangiitis Clinical Trial

Official title:
Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab

Clinical Trial Summary

This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on MabThera/Rituxan therapy by their physician according to prescribing information.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01613599
Study type Observational
Source Genentech, Inc.
Contact
Status Completed
Phase
Start date June 20, 2012
Completion date April 28, 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01729624 - PRO Development for ANCA Associated Vasculitis N/A
Terminated NCT02474888 - Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
Active, not recruiting NCT02198248 - Low-dose Glucocorticoid Vasculitis Induction Study Phase 4
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Recruiting NCT01241305 - One-Time DNA Study for Vasculitis
Completed NCT00748644 - Efficacy Study of Two Treatments in the Remission of Vasculitis Phase 3
Recruiting NCT02967068 - VCRC Tissue Repository
Completed NCT01731561 - Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Phase 3
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Completed NCT02190942 - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Terminated NCT01586858 - Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study N/A
Completed NCT00307593 - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides N/A
Completed NCT02190929 - Educational Needs of Patients With Systemic Vasculitis N/A
Terminated NCT01408836 - Plasma Exchange for Renal Vasculitis Phase 2/Phase 3
Terminated NCT05376319 - PR3-AAV Resilient Remission or PRRR Phase 2
Completed NCT02476292 - Impact of Vasculitis on Employment and Income N/A
Completed NCT02169219 - Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Phase 4
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Completed NCT00307671 - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Phase 4